- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.11.25 | OnKure Therapeutics GAAP EPS of -$1.09 | 2 | Seeking Alpha | ||
| 06.11.25 | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update | 122 | GlobeNewswire (Europe) | -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients... ► Artikel lesen | |
| 06.11.25 | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.08.25 | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08.25 | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.05.25 | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 271 | GlobeNewswire (Europe) | -- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company's... ► Artikel lesen | |
| 10.03.25 | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 360 | GlobeNewswire (Europe) | - PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,650 | -0,02 % | Dividendenbekanntmachungen (23.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALBERTSONS COMPANIES INC US0130911037 0,15 USD 0,1275 EUR BANK OF NEW YORK MELLON CORPORATION US0640581007 0,53 USD 0,4508 EUR COCA-COLA... ► Artikel lesen | |
| SANOFI | 77,24 | +0,25 % | JEFFERIES stuft SANOFI auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Sanofi auf "Buy" mit einem Kursziel von 100 Euro belassen. Sanofi sei trotz des erwarteten branchenüblichen Wachstums bis... ► Artikel lesen | |
| INNOCAN PHARMA | 4,660 | +3,10 % | Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering | HERZLIYA, Israel and CALGARY, AB, Jan. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 22,500 | +1,35 % | Gilead Exercises Option To License Assembly Bio's Helicase-Primase Inhibitor Programs | FOSTER CITY (dpa-AFX) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 30,200 | 0,00 % | NEKTAR THERAPEUTICS - 8-K, Current Report | ||
| UNITED THERAPEUTICS | 394,90 | -1,03 % | United Therapeutics reports positive phase 1 results for bioengineered liver | ||
| JAGUAR HEALTH | 0,669 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi | Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi and Canalevia-CA1, which has the potential to provide Jaguar up to an additional... ► Artikel lesen | |
| ROYALTY PHARMA | 33,930 | +0,27 % | Royalty Pharma And Teva Broaden Collaboration To Advance Potential Vitiligo Treatment | WASHINGTON (dpa-AFX) - Royalty Pharma plc. (RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), have announced a funding agreement of up to $500 million... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 64,92 | +0,09 % | Barclays startet Coverage für BridgeBio Pharma mit "Overweight"-Rating | ||
| CORBUS PHARMACEUTICALS | 7,600 | +4,11 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss | CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of... ► Artikel lesen | |
| SOLIGENIX | 1,380 | +2,99 % | SOLIGENIX, INC. - 8-K, Current Report | ||
| KALA BIO | 0,499 | +4,57 % | KALA BIO, Inc. - 8-K, Current Report | ||
| ACLARIS THERAPEUTICS | 3,351 | +13,86 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) | - ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS)... ► Artikel lesen | |
| NEUROGENE | 15,370 | -4,36 % | Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin | ||
| VYNE THERAPEUTICS | 0,565 | -0,91 % | VYNE Therapeutics: +167% für den NBC! | Kurz vor Weihnachten ist schon wieder Bescherung im No Brainer Club: VYNE Therapeutics liefert nach einem Top-Deal satte +167% Rendite innerhalb weniger Monate. Die Weihnachtsgeschenke der NBC-Mitglieder... ► Artikel lesen |
ONKURE THERAPEUTICS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 2,810 Euro und damit -1,40 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.